StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

Stock analysts at StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Down 25.5 %

Shares of Bellerophon Therapeutics stock opened at $0.01 on Friday. The business has a fifty day simple moving average of $0.03 and a 200 day simple moving average of $0.04. The stock has a market cap of $146,796.00, a PE ratio of -0.01 and a beta of 0.74. Bellerophon Therapeutics has a 12 month low of $0.01 and a 12 month high of $0.02.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.